Value of large scale expansion of tumor infiltrating lymphocytes in a compartmentalised gas-permeable bag: Interests for adoptive immunotherapy

Journal of Translational Medicine

Volumn 9, Issue , 2011, Pages

  Zuliani, Thomas ^a   David, Julien ^a   Bercegeay, Sylvain ^a   Pandolfino, Marie Christine ^a   Rodde Astier, Isabelle ^b   Khammari, Amir ^a   Coissac, Cécile ^b   Delorme, Bruno ^b   Saïagh, Soraya ^a   Dréno, Brigitte ^a  

^a HÔTEL DIEU   (France)

^b MacoPharma   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; CD4 ANTIGEN; CD8 ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; CANCER CELL CULTURE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL VIABILITY; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; GAS PERMEABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; INOCULATION; INTERMETHOD COMPARISON; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MELANOMA; PHENOTYPE; TUMOR ASSOCIATED LEUKOCYTE; CELL PROLIFERATION; CELL SURVIVAL; CULTURE TECHNIQUE; GAS; INSTRUMENTATION; METABOLISM; METHODOLOGY; PATHOLOGY; PERMEABILITY; TUMOR CELL LINE;

ANTIGENS, CD4; ANTIGENS, CD8; CD8-POSITIVE T-LYMPHOCYTES; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COCULTURE TECHNIQUES; GASES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; LYMPHOCYTES, TUMOR-INFILTRATING; PERMEABILITY;

EID: 79955881958     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-63     Document Type: Article

References (25)

1. Marijt WA, Heemskerk MH, Kloosterboer FM, Goulmy E, Kester MG, van der Hoorn MA, et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci 2003, 100:2742-2747. 10.1073/pnas.0530192100, 151411, 12601144.
2. Figlin RA, Thompson JA, Bukowski RM, Vogelzang NJ, Novick AC, Lange P, Steinberg GD, Belldegrun AS. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 1999, 17:2521-2529.
3. Dreno B, Nguyen JM, Khammari A, Pandolfino MC, Tessier MH, Bercegeay S, Cassidanius A, Lemarre P, Billaudel S, Labarriere N, Jotereau F. Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother 2002, 51:539-546. 10.1007/s00262-002-0315-1, 12384805.
4. Khammari A, Nguyen JM, Pandolfino MC, Quereux G, Brocard A, Bercegeay S, Cassidanius A, Lemarre P, Volteau C, Labarriere N, et al. Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother 2007, 56:1853-1860. 10.1007/s00262-007-0340-1, 17549472.
5. Fang L, Lonsdorf AS, Hwang ST. Immunotherapy for advanced melanoma. J Invest Dermatol 2008, 128:2596-2605. 10.1038/jid.2008.101, 18927541.
6. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA 2004, 101(Suppl 2):14639-14645. 521998, 15381769, 10.1073/pnas.0405730101.
7. Khammari A, Labarriere N, Vignard V, Nguyen JM, Pandolfino MC, Knol AC, Quereux G, Saiagh S, Brocard A, Jotereau F, Dreno B. Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones. J Invest Dermatol 2009, 129:2835-2842. 10.1038/jid.2009.144, 19554023.
8. Jotereau F, Pandolfino MC, Boudart D, Diez E, Dreno B, Douillard JY, Muller JY, LeMevel B. High-fold expansion of human cytotoxic T-lymphocytes specific for autologous melanoma cells for use in immunotherapy. J Immunother (1991) 1991, 10:405-411. 1768674, 10.1097/00002371-199112000-00003.
9. Tessier MH, Pandolfino MC, Jotereau F, Boudart D, Litoux P, Dreno B. Home therapy with autologous tumour-infiltrating lymphocytes and subcutaneous interleukin-2 in metastatic melanoma. Eur J Cancer 1996, 32A:735-736. 10.1016/0959-8049(95)00651-6, 8695283.
10. Jung T, Schauer U, Heusser C, Neumann C, Rieger C. Detection of intracellular cytokines by flow cytometry. J Immunol Methods 1993, 159:197-207. 10.1016/0022-1759(93)90158-4, 8445253.
11. Klapper JA, Thomasian AA, Smith DM, Gorgas GC, Wunderlich JR, Smith FO, Hampson BS, Rosenberg SA, Dudley ME. Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy. J Immunol Methods 2009, 30:90-99.
12. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001, 410:1107-1111. 10.1038/35074122, 11323675.
13. Chiao EY, Krown SE. Update on non-acquired immunodeficiency syndrome-defining malignancies. Curr Opin Oncol 2003, 15:389-397. 10.1097/00001622-200309000-00008, 12960522.
14. Ladanyi A, Kiss J, Somlai B, Gilde K, Fejos Z, Mohos A, Gaudi I, Tímár J. Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother 2007, 56:1459-1469. 10.1007/s00262-007-0286-3, 17279413.
15. Zhuang X, Xia X, Wang C, Gao F, Shan N, Zhang L. A high number of CD8+ T cells infiltrated in NSCLC tissues is associated with a favorable prognosis. Appl Immunohistochem Mol Morphol 2010, 18:24-28. 10.1097/PAI.0b013e3181b6a741, 19713832.
16. Zhang D, Shankar P, Xu Z, Harnisch B, Chen G, Lange C, Lee SJ, Valdez H, Lederman MM, Lieberman J. Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic. Blood 2003, 101:226-235. 10.1182/blood-2002-03-0791, 12393740.
17. Labarriere N, Pandolfino MC, Gervois N, Khammari A, Tessier MH, Dreno B, Jotereau F. Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients. Cancer Immunol Immunother 2002, 51:532-538. 10.1007/s00262-002-0313-3, 12384804.
18. Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, Finkelstein SE, Theoret MR, Rosenberg SA, Restifo NP. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 2005, 115:1616-1626. 10.1172/JCI24480, 1137001, 15931392.
19. Gattinoni L, Powell DJ, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006, 6:383-393. 10.1038/nri1842, 1473162, 16622476.
20. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, Levy D, Kubi A, Hovav E, Chermoshniuk N, Shalmon B, Hardan I, Catane R, Markel G, Apter S, Ben-Nun A, Kuchuk I, Shimoni A, Nagler A, Schachter J. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res 2010, 16:2646-2655. 10.1158/1078-0432.CCR-10-0041, 20406835.
21. Itzhaki O, Hovav E, Ziporen Y, Levy D, Kubi A, Zikich D, Hershkovitz L, Treves AJ, Shalmon B, Zippel D, Markel G, Shapira-Frommer R, Schachter J, Besser MJ. Establishment and large-scale expansion of minimally cultured "young" tumor infiltrating lymphocytes for adoptive transfer therapy. J Immunother 2011, 34:212-220. 10.1097/CJI.0b013e318209c94c, 21304398.
22. Tran KQ, Zhou J, Durflinger KH, Langhan MM, Shelton TE, Wunderlich JR, Robbins PF, Rosenberg SA, Dudley ME. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother 2008, 31:742-751. 10.1097/CJI.0b013e31818403d5, 2614999, 18779745.
23. Labarriere N, Gervois N, Bonnin A, Bouquie R, Jotereau F, Lang F. PBMC are as good a source of tumor-reactive T lymphocytes as TIL after selection by Melan-A/A2 multimer immunomagnetic sorting. Cancer Immunol Immunother 2008, 57:185-195. 10.1007/s00262-007-0361-9, 17646986.
24. Melief CJ. Cancer immunotherapy by dendritic cells. Immunity 2008, 29:372-383. 10.1016/j.immuni.2008.08.004, 18799145.
25. Huarte E, Fisher J, Turk MJ, Mellinger D, Foster C, Wolf B, Meehan KR, Fadul CE, Ernstoff MS. Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma. Cancer Lett 2009, 285:80-88. 10.1016/j.canlet.2009.05.003, 19501956.